Description

Analgesics
From Chemistry and Pharmacology to Clinical Application

**** PART 2 of 2 (pgs. 304-604) ****

Analgesics: From Chemistry and Pharmacology to Clinical Application

Edited by:
Helmut Buschmann, Thomas Christoph, Elmar Friderichs,
Corinna Maul, Bernd Sundermann

Analgesics. Edited by H. Buschmann, T. Christoph, E. Friderichs, C. Maul, B. Sundermann
Copyright © 2002 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 3-527-30403-7

ISBN: 3527304037

ISBN-10: 3527304037

ISBN-13: 9783527304035

with contributions by
Gregor Bahrenberg, Johannes Bartholomaus, Petra Bloms-Funke,
Helmut Buschmann, Thomas Christoph, Werner Englberger,
Robert Frank, Elmar Friderichs, Clemens Gillen,
Hagen-Heinrich Kennies, Ulric­h Jahnel, Corinna Maul,
Michael Przewosny, Claudia Putz, Klaus Schiene, Wolfgang Schroder,
Bernd Sundermann, Thomas Tzschentke

Hardcover: 613 pages
Publisher: Wiley-VCH; 1 edition (December 20, 2002)
Language: English
ISBN-10: 3527304037
ISBN-13: 978-3527304035

------------------------- ------------------------- ------------------------- ------

Description:

Classified by their mode of action, all important classes of analgesics are presented here, including recent developments that have not yet been introduced to the market. Altogether, more than 300 compounds are described. A carefully designed layout presents the most relevant information at a glance, including compound structure, physical properties, synthesis schemes and clinical uses. Trade names for different countries are also given, allowing quick reference to compounds currently on the market. In addition to proven pain relievers, novel approaches to pain treatment are discussed and drug candidates for future therapies are presented. With its broad scope and extensive compound listings, this is a premier reference source for pain treatment by pharmacological means. A valuable resource for clinicians, drug developers and pain researchers.

------------------------- ------------------------- ------------------------- ------

Preface:

Pain has been a human problem since the beginning of time but the last decade has
seen an explosion of information about the transmitters, receptors and channels
involved in the transmission and modulation of noxious messages generated in
peripheral tissues. This has lead to the identification of a number of potential new
targets for analgesic therapy. We now have more experimental drugs available, which
allows us to study the roles of transmitters and receptors in physiological events. There
are now numerous animal models for clinical pain states such as inflammation and
neuropathies, and these models have shown that several transmitter systems which
have minor actions in acute pains can play important roles in more persistent pains.

This ability to test drugs in contexts other than acute pain models has arisen from good
communication between bench scientists, clinicians and Industry. Until recently
investigations into the mechanisms of clinical pain syndromes all relied on animal
studies using acute stimuli. The symptoms of pain arising from nerve injury, neuropathic
pain, such as allodynia, spontaneous pain, hyperalgesia, sensory deficits and in some
cases a sympathetic component are simply not seen in the older acute models. There
are now several animal models which mimic peripheral and central neuropathic states.
The same is true for inflammation.

A number of major discoveries over the last thirty years, such as the opioid receptors
and the endogenous opioids, the spinal, supraspinal and peripheral sites of action of
opioids, the key role of glutamate in signalling in the nervous system, the important
actions of peptides such as substance P, the ability of descending controls, both
noradrenergic and serotoninergic, to influence pain transmission may not yet have
yielded many new drugs but has enormously aided the conceptual basis for
understanding pain and ana